TerminatedPhase 2NCT01559129
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung Disease
Studying Diffuse cutaneous systemic sclerosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Celgene
- Principal Investigator
- Shimon Korish, MDCelgene Corporation
- Intervention
- Pomalidomide (CC-4047)(drug)
- Enrollment
- 23 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2012 – 2016
Study locations (30)
- UCLA Division of Rheumatology, Los Angeles, California, United States
- Advances in Medicine, Rancho Mirage, California, United States
- Delaware Medical Care Associates, LLC, Newark, Delaware, United States
- Georgetown University School of Medicine, Washington D.C., District of Columbia, United States
- USF Health Faculty Office Building-FOB, Tampa, Florida, United States
- Arthritis Research and Treatment Center, Stockbridge, Georgia, United States
- University of Illinois at Chicago, Chicago, Illinois, United States
- LaPorte County Institute for Clinical Research, Inc, Michigan City, Indiana, United States
- University of Kentucky, Lexington, Kentucky, United States
- Louisiana State University, Shreveport, Louisiana, United States
- Boston University of Medicine BUMC, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- UMDNJ-Robert Wood Johnson Medical School Clinical Research Center, New Brunswick, New Jersey, United States
- North Shore-LIJ Health System-Division of Rheumatology, Great Neck, New York, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01559129 on ClinicalTrials.govOther trials for Diffuse cutaneous systemic sclerosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07473154Controlling Hyperactive Immunity With Long-lived LymphocytesQuell Therapeutics Limited
- RECRUITINGPHASE1, PHASE2NCT06947473Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.Beijing GoBroad Hospital
- RECRUITINGPHASE2NCT05029336Autologous Stem Cell Transplant (ASCT) for Autoimmune DiseasesStephan Grupp MD PhD
- RECRUITINGPHASE2NCT07047690A Study of Nemolizumab for the Treatment of Adults With Systemic SclerosisGalderma R&D
- RECRUITINGPHASE2NCT07287670EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)Mediar Therapeutics
- RECRUITINGNCT07256418Transcriptomic Study of Cutaneous Fibroblasts in SclerodermaCentre Hospitalier Universitaire Dijon
- RECRUITINGPHASE1NCT07295847A Study of AZD0120 in Autoimmune DiseasesAstraZeneca
- RECRUITINGNANCT07292961Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed With SclerodermaHacettepe University